Licensed in all 50 States

Home / Medical Weight Loss Program

WEIGHT LOSS, YOUR WAY.

Transparent pricing. Personalized care. No monthly membership fees.

Prescription treatment is available only after an appropriate medical evaluation and when clinically appropriate.

WEIGHT-MANAGEMENT BENEFITS DISCLOSURE

Every product on this page is presented in the context of weight management, appetite support, metabolic health, body composition, or an adjunctive weight-loss goal. “Potential” or “proposed” benefits describe treatment goals, pharmacologic rationale, or areas in which an ingredient or formulation has been studied or used clinically. They are not guarantees of weight loss and do not mean that FDA has approved a compounded product or an off-label use for that benefit. Individual response varies, and treatment is prescribed only when medically appropriate.

GLP-1 CONSULTATION: $125 | NON-GLP-1 WEIGHT LOSS CONSULTATION: $80 | Imperium Health Accepted Insurance Consultation: $0.00

TREATMENT GUIDED BY

Bridgett Williams-Cooper, FNP-C, PMHNP-BC

Certified in Mesotherapy and Lipolysis Injection/OBESITY MANAGEMENT, HOLISTIC MEDICINE, PEPTIDE THERAPY,  HRT, & MEN’S HEALTH

American Association of Nurse Practitioners | Personalized Treatment Planning | MSN, Chamberlain College of Nursing | MSN, Florida State University

HOW IT WORKS:

A consultation does not guarantee that a medication will be prescribed.

COMPOUNDED SEMAGLUTIDE

( This is a once weekly injection -1 month supply)

Option Cash Price
0.25 mg
$179
0.5 mg
$179
0.75 mg
$179
1 mg
$179
1.5 mg
$179
1.75 mg
$179
2 mg
$179
2.5 mg
$179

Semaglutide is a GLP-1 receptor agonist. GLP-1 signaling is involved in appetite, digestion, and glucose regulation.

Weight-management relevance / proposed benefits: Semaglutide’s GLP-1 activity may support appetite regulation, reduced food intake, improved satiety, and weight reduction when combined with appropriate nutrition and physical activity. These statements do not mean that a compounded semaglutide product is FDA-approved or therapeutically equivalent to an FDA-approved product; individual response varies.

What patients should know:

Common adverse effects can include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite.

Safety considerations:

GLP-1 treatment may not be appropriate for some patients, including those with certain endocrine, pancreatic, gastrointestinal, gallbladder, kidney, pregnancy, or medication-related considerations.

Program note:

No monthly membership fee and no dose-based price increase beyond the listed pricing structure.

Compounded semaglutide is not FDA-approved. FDA does not review compounded medications for safety, effectiveness, or quality before marketing. It should not be described as generic, identical to, or therapeutically equivalent to an FDA-approved semaglutide product.

COMPOUNDED SEMAGLUTIDE - DAILY TABLETS (30 COUNT)

( This is an once daily tablet -1 month supply)

Daily Tablet Strength Cash Price Injection-Dose Comparison*
2 mg
$127
0.25 mg weekly injection
4 mg
$140
0.5 mg weekly injection
6 mg
$155
0.75 mg weekly injection
8 mg
$167
1 mg weekly injection
10 mg
$187
1.5 mg weekly injection
12 mg
$215
2 mg weekly injection

DOSE-EQUIVALENCY GUIDANCE: Compounded oral semaglutide may be prescribed using formulation-specific oral-to-injection dose comparisons supplied by the dispensing pharmacy and prescribing clinician. Exact comparisons are patient- and formulation-specific and must follow the prescription label. This is not an FDA determination of therapeutic equivalence or interchangeability.

This is a pharmacy-compounded oral dosage form of semaglutide prescribed on an individualized basis when clinically appropriate and legally available.

Weight-management relevance / proposed benefits: A compounded oral semaglutide formulation may be considered to support appetite regulation, satiety, reduced caloric intake, and weight-management goals in appropriately selected patients. Absorption can differ by formulation, and benefits should not be assumed to match FDA-approved injectable or oral semaglutide products.

What patients should know:

Oral compounded formulations may have different absorption and exposure characteristics from FDA-approved products.

Safety considerations:

Patients should follow the exact pharmacy label and provider instructions. Use only the formulation-specific oral-to-injection comparison supplied by the dispensing pharmacy/prescribing clinician; compounded oral semaglutide is not automatically interchangeable with an injectable product.

Dose-equivalency note: Compounded oral semaglutide formulations do not have one universal oral-to-injection conversion. The injection-dose comparison must follow the specific dispensing pharmacy/prescriber’s formulation and dosing guidance. It is not an FDA determination that compounded oral semaglutide is therapeutically equivalent to or interchangeable with FDA-approved semaglutide tablets or injections.

COMPOUNDED SEMAGLUTIDE - WEEKLY TROCHES (4 COUNT)

(This is a once a week Troche Tablet - 1 month supply)

Troche Strength Cash Price Pharmacy/Provider Injection-Dose Comparison
0.75 mg
$85
0.25 mg injection
1.5 mg
$95
0.5 mg injection
3 mg
$135
1 mg injection
5.1 mg
$150
1.7 mg injection
7.2 mg
$164
2.4 mg injection

A troche is a compounded dosage form designed to dissolve in the mouth. Dose selection is individualized. *Injection-dose comparisons shown above reflect the dispensing pharmacy/provider dosing comparison used for this compounded formulation and are not an FDA determination of therapeutic equivalence or interchangeability with an FDA-approved tirzepatide injection.

Weight-management relevance / proposed benefits: A compounded semaglutide troche may be considered as a needle-free dosage-form option intended to support appetite regulation, satiety, reduced caloric intake, and weight-management goals. Clinical response and absorption may vary, and the compounded troche itself is not FDA-approved.

What patients should know:

Absorption and clinical response may vary by patient and formulation.

Safety considerations:

Use only as directed by the prescribing clinician and dispensing pharmacy.

Dose-equivalency note: The injection-dose comparisons shown for these compounded troches reflect pharmacy/provider dosing guidance for this specific formulation. Compounded semaglutide troches are not FDA-approved, and these comparisons are not an FDA determination of therapeutic equivalence or interchangeability.

COMPOUNDED TIRZEPATIDE

( This is a once weekly injection -1 month supply)

Option Cash Price
2.5 mg
$198
5 mg
$225
7.5 mg
$245
10 mg
$279
12.5 mg
$279
15 mg
$279

Tirzepatide has activity at GIP and GLP-1 receptors involved in appetite and metabolic regulation.

Weight-management relevance / proposed benefits: Tirzepatide’s GIP/GLP-1 activity may support appetite regulation, increased satiety, reduced caloric intake, metabolic improvement, and weight reduction in appropriately selected patients. These statements do not make compounded tirzepatide FDA-approved or therapeutically equivalent to Zepbound®; individual response varies.

What patients should know:

Common adverse effects can include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite.

Safety considerations:

Treatment may not be appropriate for patients with certain endocrine, pancreatic, gastrointestinal, gallbladder, kidney, pregnancy, or medication-related risk factors.

Program note:

No monthly membership fee and no dose-based price increase beyond the listed pricing structure.

Compounded tirzepatide is not FDA-approved and should not be described as generic, identical to, or therapeutically equivalent to FDA-approved Zepbound®.

COMPOUNDED TIRZEPATIDE - DAILY TABLETS

( This is an once daily tablet -1 month supply)

Option Cash Price
3 mg
Pricing coming soon
4 mg
Pricing coming soon
5 mg
Pricing coming soon
6 mg
Pricing coming soon
7 mg
Pricing coming soon
8 mg
Pricing coming soon
10 mg
Pricing coming soon
12 mg
Pricing coming soon

This is a compounded oral dosage form that may be considered only when clinically appropriate and legally available.

Weight-management relevance / proposed benefits: A compounded oral tirzepatide formulation may be considered to support appetite regulation, satiety, and weight-management goals. Oral compounded tirzepatide has not been established as therapeutically equivalent to FDA-approved injectable tirzepatide, and absorption and response may differ.

What patients should know:

Absorption and response can differ from injectable tirzepatide.

Safety considerations:

Follow the exact pharmacy label and provider instructions.

Compounded oral tirzepatide is not FDA-approved and is not represented as equivalent or interchangeable with FDA-approved tirzepatide injection.

COMPOUNDED TIRZEPATIDE - WEEKLY TROCHES (4 COUNT)

(This is a once a week Troche Tablet - 1 month supply)

Troche Dose / Injection-Dose Comparison* Cash Price
6.67 mg — Equivalent to 2.5 mg injection
$130
13.4 mg — Equivalent to 5 mg injection
$150
20 mg — Equivalent to 7.5 mg injection
$180
26.7 mg — Equivalent to 10 mg injection
$225
33.3 mg — Equivalent to 12.5 mg injection
$275
40 mg — Equivalent to 15 mg injection
$299

A troche is a compounded dosage form designed to dissolve in the mouth. Dose selection is individualized.

Weight-management relevance / proposed benefits: A compounded tirzepatide troche may be considered as a needle-free dosage-form option intended to support appetite regulation, satiety, reduced caloric intake, and weight-management goals. The compounded troche is not FDA-approved, and response and absorption may vary.

What patients should know:

Absorption and clinical response may vary by patient and formulation.

Safety considerations:

Use only as directed by the prescribing clinician and dispensing pharmacy.

Compounded tirzepatide troches are not FDA-approved. No injection-equivalency claim is made or implied.

FDA-APPROVED WEGOVY® - CASH-PAY OPTIONS

FDA-approved brand-name medication fulfilled through a participating dispensing pharmacy when prescribed and available.

(This is the non-compounded form of Semaglutide)

Option Cash Price
0.25 mg pen
$299
0.5 mg pen
$299
1 mg pen
$449
1.7 mg pen
$449
2.4 mg pen
$449
7.2 mg Wegovy® HD pen
$499
Oral Wegovy® Cash Price
1.5 mg tablet – 30 count
$249
4 mg tablet – 30 count
$299
9 mg tablet – 30 count
$399
25 mg tablet – 30 count
$399

FDA-approved brand-name medication fulfilled through a participating dispensing pharmacy when prescribed and available.

Wegovy® (semaglutide) is an FDA-approved GLP-1 receptor agonist available in once-weekly injection and once-daily tablet forms for FDA-approved indications in eligible patients.

FDA-approved weight-management benefit: Wegovy® is approved for chronic weight management in eligible patients when used with reduced-calorie nutrition and increased physical activity. Semaglutide may help reduce appetite and caloric intake and can support clinically meaningful weight reduction in appropriate patients. Results vary.

What patients should know:

Common adverse effects include gastrointestinal symptoms such as nausea, diarrhea, vomiting, constipation, and abdominal discomfort.

Safety considerations:

Wegovy® carries a boxed warning regarding thyroid C-cell tumors observed in rodents and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Additional warnings and precautions apply.

Wegovy® is a registered trademark of Novo Nordisk. Imperium Health is an independent healthcare practice and is not affiliated with or endorsed by Novo Nordisk unless expressly stated otherwise. Cash-pay pricing and availability may change.

FDA-APPROVED ZEPBOUND® - CASH-PAY OPTIONS

( This is the non-compounded form of Tirzepatide )

Option Cash Price
2.5 mg – 1 month supply
$399
5 mg – 1 month supply
$499
7.5 mg – 15 mg – 1 month supply
$549

Zepbound® (tirzepatide) is an FDA-approved GIP/GLP-1 receptor agonist used with reduced-calorie nutrition and increased physical activity for FDA-approved indications in eligible patients.

FDA-approved weight-management benefit: Zepbound® is approved for chronic weight management in eligible patients when used with reduced-calorie nutrition and increased physical activity. Tirzepatide may help reduce appetite and caloric intake and can support clinically meaningful weight reduction in appropriate patients. Results vary.

What patients should know:

Common adverse effects include nausea, diarrhea, vomiting, constipation, abdominal discomfort, dyspepsia, and other gastrointestinal symptoms.

Safety considerations:

Zepbound® carries a boxed warning regarding thyroid C-cell tumors observed in rats and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Additional warnings and precautions apply.

Zepbound® is a registered trademark of Eli Lilly and Company. Imperium Health is an independent healthcare practice and is not affiliated with or endorsed by Eli Lilly unless expressly stated otherwise. Cash-pay pricing and fulfillment format may vary by pharmacy, dose, and availability.

SLIMPHEN - 30 COUNT

Option Cash Price
Yohimbine HCl / Caffeine / L-Theanine
$90

A compounded stimulant-containing formulation. It should not be represented as an FDA-approved weight-loss drug.

Weight-management relevance / proposed benefits: Based on its ingredients, this compounded formulation may be intended to support appetite control, alertness, energy, or adherence to a clinician-directed weight-management plan. The compounded combination is not FDA-approved for weight loss, and these potential effects are not guaranteed.

Safety considerations:

Possible effects may include increased heart rate, increased blood pressure, anxiety, tremor, restlessness, or insomnia. Individual response varies.

BELLA CAPSULES - 30 COUNT

Option Cash Price
Topiramate 15 mg / Bupropion 65 mg / Naltrexone 18 mg / Vitamin B12 1 mg / Phentermine 20 mg
$125

A compounded multi-ingredient prescription formulation used only after individualized clinical evaluation.

Weight-management relevance / proposed benefits: The ingredients in this compounded formulation act through different pathways that may be used to support appetite control, cravings, eating behavior, and weight-management goals in selected patients. The compounded combination itself is not FDA-approved for obesity and should not be considered equivalent to an FDA-approved combination product.

Safety considerations:

Because the formulation contains several prescription ingredients, screening should include cardiovascular history, seizure risk, opioid use, psychiatric history, pregnancy potential, medication interactions, and other relevant contraindications.

METFORMIN - 30 COUNT

Option Cash Price
Metformin 500 mg
$55

Metformin is FDA-approved primarily for type 2 diabetes. A healthcare professional may prescribe an FDA-approved medication for another medically appropriate use when permitted by law.

Why it may be used off-label in weight management: Clinicians sometimes include metformin in weight-management plans, particularly when insulin resistance, prediabetes, type 2 diabetes, or polycystic ovary syndrome (PCOS)-related metabolic concerns are present. Clinical studies suggest modest average reductions in weight or BMI in some adults with overweight or obesity, but individual response varies. Metformin is not FDA-approved specifically for obesity or weight loss.

Weight-management relevance / proposed benefits: In selected patients, metformin may support insulin sensitivity, glucose regulation, and modest weight reduction, particularly when metabolic conditions such as insulin resistance, prediabetes, type 2 diabetes, or PCOS-related metabolic concerns are present. Weight-loss response varies, and metformin is not FDA-approved specifically for obesity.

Safety considerations:

Metformin is not FDA-approved specifically as a weight-loss medication. Gastrointestinal adverse effects are common, and kidney function and other clinical factors may require review.

PHENTERMINE - 30 COUNT

Option Cash Price
Phentermine 37.5 mg (shipped)
$90
Phentermine 37.5 mg, pharmacy pickup
$80 appointment fee; medication typically $15–$25 at the pharmacy

Phentermine is a prescription sympathomimetic medication used for short-term weight management in appropriate patients.

Potential benefit: In appropriately selected patients, phentermine may reduce appetite and support short-term weight reduction when used as part of a clinician-directed program that includes nutrition and physical activity. Results vary, and controlled-substance prescribing is subject to medical and legal requirements.

Safety considerations:

Phentermine is a controlled substance. It may increase heart rate or blood pressure and can cause palpitations, insomnia, restlessness, or dry mouth. Controlled-substance prescribing is never guaranteed and is subject to clinical judgment and applicable law.

PHENTERMINE + TOPIRAMATE - 30 COUNT

Option Cash Price
Phentermine HCl / Topiramate immediate release 15/20 mg (shipped)
$112
Phentermine HCl / Topiramate immediate release / slow release 15/12.5 mg (shipped)
$125
FDA Approved Qsymia -80.00 consult fee
Varies based on pharmacy price.

These are compounded combinations containing phentermine and topiramate.

Why this combination may be used for weight management: An FDA-approved extended-release phentermine/topiramate product exists for chronic weight management in eligible patients. The compounded formulations listed here are different formulations and are not FDA-approved Qsymia®, generic Qsymia®, or established as therapeutically equivalent to Qsymia®. Any use is individualized by the prescriber.

Weight-management relevance / proposed benefits: Phentermine and topiramate affect appetite and food intake through different mechanisms and may support reduced hunger, improved satiety, and weight reduction in selected patients. The compounded formulations listed here are not FDA-approved Qsymia® and are not established as therapeutically equivalent to it.

Safety considerations:

They are not FDA-approved Qsymia® and should not be represented as generic, equivalent, or interchangeable with Qsymia®. Topiramate may cause fetal harm; pregnancy-related precautions are important.

NALTREXONE - 30 COUNT

Option Cash Price
1.5 mg, 3 mg, 4 mg, 5 mg, 6 mg, or 8 mg
$60

Naltrexone is FDA-approved for certain substance-use disorders and may be used in clinician-directed treatment strategies when medically appropriate.

Why it may be used off-label in weight management: Naltrexone affects opioid-receptor pathways involved in reward and eating behavior and may sometimes be incorporated into an individualized weight-management plan. Evidence for naltrexone alone as a weight-loss medication is limited; it should not be promoted as a proven stand-alone obesity treatment. An FDA-approved weight-management product, Contrave®, combines naltrexone with bupropion.

Weight-management relevance / proposed benefits: Naltrexone may influence reward-related eating pathways and may be considered in selected patients when cravings or compulsive eating patterns are part of the treatment plan. Naltrexone alone is not FDA-approved for weight loss, and evidence for stand-alone weight reduction is limited.

Safety considerations:

Naltrexone alone is not FDA-approved as a weight-loss medication. It blocks opioid effects and can precipitate withdrawal in a patient who is physically dependent on opioids.

CONTRAVE® - 30 COUNT

Option Cash Price
Naltrexone 8 mg / Bupropion 90 mg
$235

Contrave® is an FDA-approved prescription combination used for chronic weight management in certain eligible adults together with nutrition and physical activity.

FDA-approved weight-management benefit: Contrave® combines naltrexone and bupropion and may help reduce appetite and food cravings as part of chronic weight management in eligible adults when combined with nutrition and physical activity. Individual response varies.

Safety considerations:

Important considerations include seizure history, uncontrolled hypertension, eating disorders, opioid use, medication interactions, and psychiatric warnings associated with bupropion.

TOPIRAMATE - 30 COUNT

Option Cash Price
25 mg
$65
50 mg
$85

Topiramate is FDA-approved for certain neurologic conditions and may be prescribed off-label for other medically appropriate uses.

Why it may be used off-label in weight management: Topiramate can reduce appetite and food intake in some patients and has demonstrated weight reduction in clinical studies. Topiramate alone is not FDA-approved for obesity; however, topiramate is one component of the FDA-approved weight-management medication Qsymia® when combined with phentermine in a specific extended-release formulation. Treatment must be individualized because neurologic, psychiatric, metabolic, pregnancy-related, and other adverse effects can occur.

Weight-management relevance / proposed benefits: When used off-label in selected patients, topiramate may reduce appetite, decrease food intake, and support weight reduction. Topiramate alone is not FDA-approved for obesity, and its risks and benefits must be individualized.

Safety considerations:

Topiramate alone is not FDA-approved specifically as a weight-loss medication. Possible adverse effects include tingling, cognitive slowing, dizziness, taste changes, and mood changes. It may cause fetal harm.

LIPO STAT - COMPOUNDED INJECTION SUPPORT

Option Cash Price
5-week supply
$130
10-week supply
$180

Contains methionine 15 mg, choline chloride 50 mg, L-carnitine 25 mg, and methylcobalamin 0.6 mg according to the listed formulation.

Weight-management relevance / proposed benefits: This compounded combination may be used as an adjunct within a broader clinician-directed weight-loss program to support nutritional and metabolic needs while patients work on calorie reduction, physical activity, and sustainable weight-loss behaviors. Ingredients such as methionine, choline, L-carnitine, and methylcobalamin participate in normal metabolic pathways. This formulation is not FDA-approved for weight loss or fat reduction, and it is not represented as a stand-alone fat-burning treatment or a guarantee of weight loss.

Safety considerations:

Individual response varies. Do not rely on this product as a substitute for nutrition, activity, or evidence-based obesity treatment.

This compounded combination is not FDA-approved for weight loss or fat reduction. Imperium Health does not guarantee increased energy, fat burning, accelerated metabolism, or a specific amount of weight loss.

TESAMORELIN / IPAMORELIN - COMPOUNDED THERAPIES

Option Cash Price
Pharmacy-prepared Tesamorelin / Ipamorelin 5-week supply
$186
Lyophilized 5 mg – bacteriostatic water included when supplied
$75
Lyophilized 10 mg – bacteriostatic water included when supplied
$100
Lyophilized 20 mg – bacteriostatic water included when supplied
$125

These are clinician-directed compounded peptide formulations. Lyophilized products require reconstitution exactly as directed by the dispensing pharmacy.

Weight-management relevance / proposed benefits: Within a weight-loss or body-composition program, some clinicians may consider this compounded peptide combination as an adjunct for body-composition goals or growth-hormone-axis support in carefully selected patients. It should not be presented as a primary obesity medication or as a substitute for FDA-approved weight-loss therapy. Tesamorelin has an FDA-approved indication that is separate from general weight loss, while ipamorelin is not FDA-approved. The compounded combination is not FDA-approved for obesity or generalized weight loss, and results are not guaranteed.

Safety considerations:

Peptide formulations can have formulation, immunogenicity, impurity, and route-specific safety considerations. Treatment should be considered only after individualized risk-benefit review.

A compounded tesamorelin/ipamorelin combination is not FDA-approved for weight loss. Ipamorelin is not an FDA-approved drug. Availability is subject to applicable law, pharmacy policy, and clinical appropriateness.

CJC-1295 / IPAMORELIN - COMPOUNDED THERAPIES

Option Cash Price
Pharmacy-prepared CJC-1295 / Ipamorelin 5-week supply
$186
Lyophilized CJC-1295 / Ipamorelin 5 mg / 5 mg – bacteriostatic water included when supplied
$75

These are clinician-directed compounded peptide formulations. Lyophilized products require reconstitution exactly as directed by the dispensing pharmacy.

Weight-management relevance / proposed benefits: Within a broader weight-loss or body-composition program, some clinicians may consider compounded CJC-1295/ipamorelin as an adjunct for body-composition support while patients continue nutrition, activity, and other medically appropriate weight-management treatment. These proposed uses are not FDA-approved indications. The compounded combination is not FDA-approved for obesity or weight loss and should not be presented as a stand-alone fat-loss treatment; clinical benefit is not guaranteed.

Safety considerations:

Potential risks and uncertainties should be discussed before treatment. Do not use promotional claims promising fat loss, muscle gain, anti-aging effects, or guaranteed body-composition changes.

CJC-1295/ipamorelin compounded preparations are not FDA-approved for weight loss. Availability is subject to applicable law, pharmacy policy, and clinical appropriateness.

LIPO SCULPT - COMPOUNDED TOPICAL OPTIONS

Option Cash Price
Lipo Sculpt Cream – Aminophylline 0.5%, 60 mL
$91.55
Lipo Sculpt Lean – Aminophylline / 7-Keto DHEA / Phenylephrine HCl 0.5% / 2.5% / 0.25%, 60 mL
$117.68
Lipo Sculpt Max – Aminophylline / 7-Keto DHEA 0.5% / 5%, 60 mL
$105.71

These are compounded topical prescription options.

Weight-management relevance / proposed benefits: These compounded topical formulations may be offered as an optional body-contouring adjunct for patients participating in a broader weight-loss program who are concerned about the cosmetic appearance of localized areas, skin texture, or contour. They do not treat obesity and are not substitutes for nutrition, physical activity, or prescription weight-loss therapy. They are not FDA-approved to cause weight loss, eliminate cellulite, tighten loose skin, or guarantee localized fat reduction, and individual cosmetic response varies.

Safety considerations:

Skin irritation and other adverse reactions are possible. Individual response varies.

These compounded topical formulations are not FDA-approved to cause weight loss, eliminate cellulite, tighten loose skin, or guarantee localized fat reduction.

SPECIALTY / NON-FDA-APPROVED & COMPOUNDED OPTIONS

The products in this section have different regulatory status from FDA-approved prescription weight-loss medications. They are listed with prominent status disclosures so patients can make an informed decision. Availability is subject to provider evaluation, applicable federal and state law, product sourcing, pharmacy requirements when applicable, and current regulatory requirements. Listing a product or price does not guarantee that it can legally or clinically be provided to a particular patient.

LEMON BOTTLE - 10 mL

Option Cash Price
10 mL
$50

Lemon Bottle is a cosmetic treatment marketed for targeted fat reduction in areas such as under the chin and along the body. At Imperium Health, we begin with a consultation to discuss your goals, assess the area, and review whether treatment is appropriate for you. Results vary, and multiple sessions may be needed.

Lemon Bottle is not FDA approved as an injectable fat dissolving treatment. The FDA has identified it as an unapproved drug .

COMPOUNDED ORFORGLIPRON - 6 mg CAPSULES

Option Cash Price
6 mg capsules – 30 count
$135

Product education & regulatory disclosure: Orforglipron is an oral GLP-1 receptor agonist. FDA-approved orforglipron is marketed as Foundayo™ in specific FDA-approved strengths. This separately compounded 6 mg capsule is NOT FDA-approved and is not generic Foundayo™, therapeutically equivalent to Foundayo™, or interchangeable with Foundayo™. Compounded orforglipron may be prescribed or dispensed only when the treating clinician and dispensing pharmacy determine that the patient-specific prescription is clinically appropriate and legally permissible under current compounding laws. Availability may change without notice based on FDA status, commercial availability, pharmacy policy, or regulatory requirements. Common GLP-1 class effects may include nausea, vomiting, diarrhea, constipation, abdominal discomfort, and reduced appetite; serious adverse effects may occur. Individual eligibility requires medical evaluation.

Weight-management relevance / proposed benefits: Orforglipron is a GLP-1 receptor agonist, and GLP-1 activity is directly relevant to medical weight management because it may support appetite regulation, satiety, reduced caloric intake, and weight reduction. The compounded 6 mg capsule is not FDA-approved, and its safety, effectiveness, absorption, and dose response should not be assumed to be equivalent to FDA-approved Foundayo™.

Weekly mobile shots

Option Cash Price
GLP consult
$125
Non GLP consult
$80
Accepted Insurance weight loss consult
$0.00

In-Person Weekly Shots

LOCAL WEEKLY INJECTION PROGRAM

ALL WEEKLY SHOTS ARE PATIENT-SPECIFIC.

Medicare Part D

$50/MONTH GLP-1 BRIDGE PROGRAM

Eligible Medicare Part D beneficiaries may qualify for the Medicare GLP-1 Bridge program.

$50

PER MONTH FOR ELIGIBLE PATIENTS

Medicare Part D patients: book an Insurance-Covered Primary Care visit to discuss eligibility for the Medicare GLP-1 Bridge program. Eligible patients may qualify for certain covered GLP-1 medications for $50/month. Eligibility criteria, prior authorization, medication, formulation, and program terms apply. Coverage is not guaranteed.

Call (321) 795-1156 to ask about eligibility.

Before You Start

CONSULTATION & TELEHEALTH REQUIREMENTS

Consult Type Consult Fee
GLP-1 consultation – semaglutide, tirzepatide, Wegovy®, Zepbound®
$125
Non-GLP-1 weight loss consultation
$80
Imperium Approved Insurance (Please check the insurance page to confirm we accept your insurance before booking )
0.00

Transparent pricing · No monthly membership fees

READY TO GET STARTED?

Book a telehealth consultation with a licensed healthcare professional. Consult price is applied toward the qualifying medication cost when medication is prescribed through the applicable program.

text or call our secure line  (321) 795-1156

IMPORTANT PRESCRIPTION, COMPOUNDING & MEDICAL DISCLOSURE

Prescription medications are available only after an appropriate medical evaluation and when determined medically appropriate by a licensed healthcare professional.

Compounded medications: Compounded medications are not FDA-approved. FDA does not review compounded medications for safety, effectiveness, or quality before marketing. A compounded medication should not be described as an FDA-approved drug, a generic version of an FDA-approved drug, identical to an FDA-approved drug, or therapeutically equivalent to an FDA-approved drug unless that claim has been established through an applicable FDA approval pathway.

Individualized treatment: Medication selection, formulation, strength, route, dose, quantity, titration, and duration of therapy are individualized. Listing a medication, strength, formulation, or price on this website does not guarantee that the medication will be prescribed or available for a particular patient.

Off-label prescribing: Healthcare professionals may prescribe an FDA-approved medication for a medically appropriate use that differs from its FDA-approved labeling when permitted by law. Information about an off-label use does not mean FDA has approved that medication for the off-label use.

Website education about an off-label use is intended to explain why a clinician may consider a medication; it is not a claim that the use is FDA-approved, appropriate for every patient, or guaranteed to produce weight loss.

Pricing: Prices shown are cash-pay prices unless otherwise stated and may change based on dose, quantity, formulation, pharmacy, manufacturer pricing, shipping, medication availability, regulatory requirements, or patient-specific clinical needs.

Insurance: Insurance verification, benefit estimates, and prior-authorization submissions are not guarantees of coverage or payment. Patients are responsible for applicable deductibles, copays, coinsurance, noncovered services, and other patient financial responsibility.

Results: Individual results vary. Imperium Health does not guarantee a specific amount or rate of weight loss, appetite suppression, a particular body weight or BMI, localized fat loss, improvement of a specific condition, or freedom from adverse effects.

Telehealth: Telehealth treatment is available only when the treating professional is legally authorized to treat the patient in the jurisdiction where the patient is physically located at the time of the encounter. In-person examination, laboratory testing, records, specialist evaluation, or other testing may be required before treatment is initiated or continued.

Controlled substances: Certain weight-management medications are controlled substances. Controlled-substance prescribing is subject to applicable federal and state law, DEA requirements, prescription drug monitoring review when required, clinical appropriateness, contraindication screening, and provider judgment. A controlled-substance prescription is never guaranteed.

Emergency care: This website is not intended for emergency medical care. Call 911 or seek emergency medical attention for a medical emergency.

Trademarks: Brand names and trademarks are the property of their respective owners. Their use is for identification and patient education only and does not imply sponsorship, affiliation, endorsement, or partnership with Imperium Health unless expressly stated.